Home | Medical Need | R&D Programmes | Company | Collaborations | News |
Northern Antibiotics has developed two series of novel compounds that are highly active against difficult-to-treat Gram-negative bacteria such as multi-resistant Escherichia coli, Klebsiella pneumoniae, other species of Enterobacteriaceae, and Acinetobacter baumannii. The first series is directly antibacterial and includes a compound with a remarkable activity against Pseudomonas aeruginosa, too. The second series sensitizes Gram-negative enteric bacteria and Acinetobacter by more than 100 times to the action of antibiotics usually used for the treatment of Gram-positive infections only. The lead compounds of both series are in late preclinical development. The results from both in vitro and in vivo studies indicate the desired efficacy and safety profile. Northern Antibiotics has filed both U.S. and Patent cooperation Treaty (PCT) patent applications claiming composition-of-matter, pharmaceutical compositions and therapeutic uses of the compounds. | |
| |
Novel Polymyxins for the treatment of serious Gram-negative hospital infections | |
|
Mailing Address: P.O.Box 30, FIN-00721, Helsinki, Finland
Visiting Address: Eskolantie 1, FIN-00720, Helsinki, Finland
Phone: + 358-50-355 0822
Fax: +358-9-6842 0130
E-mail: info@northernantibiotics.com
